e-learning
resources
Virtual 2020
Pre-Congress Content
What is hot in idiopathic pulmonary fibrosis?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The value of the surprise question to predict mortality in idiopathic pulmonary fibrosis
N. Tak (Rotterdam, Netherlands), C. Moor (Rotterdam, Netherlands), C. Owusuaa (Rotterdam, Netherlands), C. Van Der Rijt (Rotterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands)
Source:
Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis?
Session:
What is hot in idiopathic pulmonary fibrosis?
Session type:
E-poster session
Number:
1800
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Tak (Rotterdam, Netherlands), C. Moor (Rotterdam, Netherlands), C. Owusuaa (Rotterdam, Netherlands), C. Van Der Rijt (Rotterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands). The value of the surprise question to predict mortality in idiopathic pulmonary fibrosis. 1800
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
When to refer patients with advanced COPD to palliative care services
Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma
Beyond palliative care: tackling the origins of asthma
Related content which might interest you:
The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?
Source: Eur Respir J, 51 (1) 1702420; 10.1183/13993003.02420-2017
Year: 2018
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema
Source: Eur Respir J 2011; 37: 176-183
Year: 2011
A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 36: 1067-1072
Year: 2010
Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Is age a predictor in prognosis of patients with idiopathic pulmonary fibrosis?
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 25: 96-103
Year: 2005
HRCT score to control and evaluate the prognosis in idiopathic pulmonary fibrosis
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?
Source: Eur Respir J, 57 (3) 2004562; 10.1183/13993003.04562-2020
Year: 2021
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (1) 00096-2016; 10.1183/23120541.00096-2016
Year: 2017
Hyaluroman syntehase-2 over expression has impact in the evolution and on the prognosis of idiopathic pulmonary fibrosis patients
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
The impact of a network based approach on lung function and symptom duration at diagnosis in idiopathic pulmonary fibrosis
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Source: Eur Respir Rev, 28 (153) 190044; 10.1183/16000617.0044-2019
Year: 2019
Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018
Pulmoanry hypertension is a negative prognostic factot of long term survival in patients with idiopathic pulmonary fibrosis after lung transplantation
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis?
Source: Eur Respir J 2003 Dec 01;22(6):906-911
Year: 2003
Towards a better diagnosis of idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2011; 20: 108-113
Year: 2011
Idiopathic pulmonary fibrosis: tracking the true occurrence is challenging
Source: Eur Respir J 2015; 46: 604-606
Year: 2015
Novel CT markers of volume loss in idiopathic pulmonary fibrosis (IPF) predict mortality
Source: International Congress 2017 – Novel imaging findings characterising various lung diseases and their prognoses
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept